News

Ocugen to Showcase Innovations at Upcoming Gene Meeting

Ocugen to Showcase Innovations at Upcoming Gene Meeting

Ocugen's Participation in the Cell & Gene Meeting

Ocugen, Inc. (NASDAQ: OCGN), a prominent biotechnology company dedicated to innovative gene and cell therapies, has announced a significant upcoming presentation. Dr. Shankar Musunuri, Chairman and Chief Executive Officer, will take center stage at the 2024 Cell & Gene Meeting on the Mesa. This esteemed event is set to bring together industry leaders to discuss groundbreaking developments and strategies in translating science into viable treatments.

Overview of Dr. Musunuri's Presentation

Dr. Musunuri's presentation is expected to shed light on Ocugen's pioneering modifier gene therapy platform, a forefront solution aiming to tackle complex retinal diseases. The session will include insights into several key clinical trials, such as the Phase 3 liMeliGhT trial, focused on treating retinitis pigmentosa, along with the Phase 2 ArMaDa trial targeting geographic atrophy and the Phase 1/2 GARDian trial addressing Stargardt disease. With the Phase 3 trial currently in progress, Ocugen is on track to potentially meet its 2026 targets for Biologics License Application (BLA) and Marketing Authorization Application (MAA) approvals.

Importance of the Cell & Gene Meeting

The Cell & Gene Meeting on the Mesa serves as a crucial platform for industry stakeholders to converge and share knowledge on the latest advancements in regenerative medicine. The event emphasizes the urgent need for innovative solutions in areas where treatment options are scarce. Dr. Musunuri expressed the significance of this gathering, highlighting the role of the Alliance for Regenerative Medicine in championing new therapies that prioritize patient care and well-being.

Event Details

Details of the presentation are as follows:

Date: Monday, October 7, 2024
Time: 1:30 p.m. MST
Location: Arizona Biltmore, FLW, Ballroom F

For those unable to attend in person, virtual participation is available, including options for live streaming and on-demand viewing of all conference sessions.

About Ocugen, Inc.

Ocugen, Inc. is at the forefront of biotechnology, striving to transform patient care through innovative gene and cell therapies. The company is committed to making meaningful contributions to health by developing therapies that address unmet medical needs across various conditions. Ocugen's modifier gene therapy platform holds the potential to provide solutions for multiple retinal diseases with a single therapeutic product. In addition, the company is actively engaged in research aimed at enhancing public health through its work in infectious diseases and orthopedic conditions.

Connect with Ocugen

To learn more about Ocugen and its innovative therapies, visit www.ocugen.com. You can also follow the company on social media for the latest updates.

Frequently Asked Questions

What is the focus of Ocugen, Inc.?

Ocugen specializes in discovering and developing novel gene and cell therapies and vaccines to improve health outcomes.

Who will present at the 2024 Cell & Gene Meeting on the Mesa?

Dr. Shankar Musunuri, CEO of Ocugen, will present key insights on their gene therapy innovations.

What are the key clinical trials mentioned by Ocugen?

Ocugen highlighted three major trials: OCU400 Phase 3 liMeliGhT for retinitis pigmentosa, OCU410 Phase 2 ArMaDa for geographic atrophy, and OCU410ST Phase 1/2 GARDian for Stargardt disease.

When and where is the event taking place?

The event is set for October 7-9, 2024, at the Arizona Biltmore, with Dr. Musunuri's presentation scheduled for October 7 at 1:30 p.m. MST.

How can one participate virtually in the event?

Virtual attendance provides access to live streams and on-demand viewings of the conference presentations and sessions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Fractal Sees Explosive Q2 Gain: Revenue Hits $100M

Updated Category News Views 93

Fractal’s Revenue Moment: Climbing New Peaks Fractal Analytics just knocked it out of the park, folks. Imagine this—an AI company pulling in $100 million for the first quarter, getting a 20% jump in revenue year on year. That's right, these numbers aren't just fancy figures; they're staggering proof that Fractal's hitting its AI stride. The healthcare and life...

Continue Reading
Black Friday Doubt Grows: Just 54% Trust Real Deals

Updated Category News Views 93

Do Shoppers Believe in Black Friday Anymore? You'd think by now, retailers would have cracked the code on building trust with their customers. But guess what? A fresh survey from Boston Consulting Group reveals only 54% of consumers buy the whole Black Friday discount story. That's barely more than flipping a coin. Promotion Fatigue: The Trust Buster Funny thing,...

Continue Reading
Chord's Zenlytic Move: A Power Play in AI Expansion

Updated Category News Views 90

Chord's Bold Acquisition: Zenlytic Joins the Fold In a gutsy move that’s got folks buzzing, Chord has pulled Zenlytic into its orbit. Announced with a bang on November 3, 2026, this acquisition isn't just some flimsy, seasonal grab. They're doubling down on AI and doubling their revenue while they're at it. Now, brace yourselves: with giants like Verizon, J.Crew,...

Continue Reading
Globee® AI Awards Calls For Global Innovation Entries

Updated Category News Views 30

Rolling Out the Red Carpet for AI Innovators Worldwide Here's a call to all the boundary-pushing eggheads tinkering with artificial intelligence. The Globee® Awards is opening its doors again for the 3rd Annual AI showdown, inviting nominations from the creative minds conjuring up AI magic across the globe. This ain't your grandma's science fair; we're talking real-world...

Continue Reading
Crude Insight: Refining Margins Expand, LNG Orders Rise

Updated Category News Views 147

Refining Margins Stretch While LNG Orders Surge Well, folks, oil markets have sure been a rollercoaster lately. WTI futures danced all over the place, closing near $96 a barrel after brushing against both $93 and $99 earlier this week. Brent wasn't left out of the tango, setting at $103.60. Everyone's holding their breath each time these numbers come through. Energy...

Continue Reading
Marc Majors Takes Helm as GESMN Service Chief

Updated Category News Views 80

Marc Majors: Leading the Charge at GESMN Every now and then, an organization gets a shot of adrenaline that could redefine its path—or so they hope. Marc Majors stepping into the role of Chief Services & Programs Officer at Goodwill-Easter Seals Minnesota (GESMN) might just be one of those moments. This isn't just a title transfer. It's a whole strategic shift, folks....

Continue Reading
Mind Meets Soul: Neuroscience and Spiritual Pathways

Updated Category News Views 101

The Brain, Stress, and Spiritual Practices Ever tried to meditate and wondered if it actually does a number on your mind? Well, here comes Dr. Helen Lavretsky, who’s delving into the nitty-gritty of what happens up there when stress hits and spirituality steps in. This session on November 10 is bound to be a humdinger in the realm of science-meets-spirit. If you've ever...

Continue Reading
Protein Dynamics: Insights into DNA Maintenance

Updated Category News Views 81

Unlocking the Mechanics of DNA Handling If there's one thing that drives scientific snooping, it's the quest for details as minute as a fly speck on an elephant. Over at Kanazawa University, scientists have peeled back the curtain on an intriguing game of molecular ballet. What they've used to catch this dance in action? High-speed atomic force microscopy, that’s what....

Continue Reading
Flexcompute's Physics Twin Revolutionizes Space Docking

Updated Category News Views 23

There's a new player shaking up the space game, and it's called the Physics Twin. Flexcompute, a trailblazer in AI-driven physics modeling, just rolled this out to help figure out how thruster plumes mess with nearby spacecraft. Trust me, this ain't your garden-variety simulation tool. Why Thruster Plumes Matter If you're in the business of dancing spacecraft around each...

Continue Reading
Japan's RWE Market Transformation: TXP's Insightful Whitepaper

Updated Category News Views 55

Unraveling the Real-World Evidence Landscape in Japan The folks at TXP Medical just dropped a bombshell of a whitepaper that'll have Medical Affairs departments buzzing. Imagine waking up to a market that's exploding by over 500% in just a decade—yeah, I'm talking about the EMR-derived data market in Japan. These guys are saying it's gonna shoot from ¥3.9 billion in...

Continue Reading

Top 5 Most Recently Viewed Articles

Mizuho Stays Neutral on Super Micro Amid Delisting Concerns

Updated Category News Views 160

Mizuho Maintains Neutral Outlook on Super Micro Mizuho Financial Group recently reaffirmed its neutral rating for Super Micro Computer (NASDAQ: SMCI) while setting a price target of $45.00. This stance arises from ongoing worries about the company's internal financial controls and potential risks of being delisted from the NASDAQ, which could significantly impact its...

Continue Reading
Kyverna Therapeutics Investors: Join the Fight for Justice

Updated Category News Views 197

Investors Mobilize Against Securities Fraud In a significant development, the Schall Law Firm has taken the lead in filing a class action lawsuit against Kyverna Therapeutics, Inc. (NASDAQ: KYTX). This legal action emphasizes the importance of ensuring that companies are transparent and truthful in their communications with investors. The firm specializes in representing...

Continue Reading
Understanding Life Science REIT Plc's Recent Position Disclosure

Updated Category News Views 128

Key Information About Life Science REIT Plc Life Science REIT Plc, a company focused on creating spaces that foster innovation in the life sciences sector, recently made a position disclosure regarding ownership interests. This disclosure is particularly important for investors and market analysts as it reflects the shareholder structure, and can influence decisions in...

Continue Reading
Lumen Technologies Set to Release Key Financial Results Soon

Updated Category News Views 187

Anticipation for Lumen Technologies' Q1 Earnings Report Lumen Technologies (NYSE: LUMN), renowned for providing a robust network that integrates artificial intelligence, is poised to announce its financial results for the first quarter. Investors and stakeholders alike await these results with keen interest, as they will showcase the company's financial performance and...

Continue Reading
Why Bundling Insurance Policies Might Save Time

Updated Category News Views 18

Understanding Insurance Bundling In this fast-paced world where even the toaster thinks it's smarter than you, insurance might seem like a relic. But bundling policies—now that's something even the technophobes can dig. HelloNation brought in Sam Kessler, the insurance whiz from Strongsville, to lay it down. Simplifying Insurance Management Kessler's take? Bundling your...

Continue Reading